Pharvaris N.V. - Ordinary Shares (PHVS)
PHVS moved a median of 0.00% 30 minutes after news, and -0.46% by the close. How PHVS actually reacts to news — the realized, point-in-time move the market made, measured across 286 labeled events over the last three years with zero look-ahead.
PHVS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 251 |
| 30-min | 0.00% | 47% | 280 |
| 60-min | -0.26% | 40% | 284 |
| to close | -0.46% | 39% | 286 |
| Middle 50% of PHVS reactions | -1.07% to +0.83% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 286 |
Half of all Pharvaris N.V. - Ordinary Shares news events land between -1.07% and +0.83% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PHVS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | -0.78% | 31% | -1.77% |
| Coverage initiations | 23 | -0.94% | 30% | -1.13% |
| Rating reiterations | 67 | -1.02% | 30% | -1.28% |
| Price-target raises | 15 | -1.02% | 27% | -1.93% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how PHVS ranks against every other measured name →
That’s how PHVS usually reacts — get an email when it moves on news →Email me when PHVS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PHVS's baseline. Nothing else.
Recent PHVS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K Pharvaris N.V. For: Sep 08 | SEC filing · Form 6-K | SEC EDGAR | +0.81% | -7.00% | |
| Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks | Press release | GlobeNewswire | +0.81% | -7.00% | |
| Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026 | Press release | GlobeNewswire | -0.59% | +0.76% | |
| Form 6-K Pharvaris N.V. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -0.18% | +7.14% | |
| Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.18% | +7.14% | |
| Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology | Press release | GlobeNewswire | +1.28% | +2.53% | |
| Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema | Press release | GlobeNewswire | -1.05% | -0.87% | |
| Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks | Press release | GlobeNewswire | +1.06% | -2.29% | |
| Form 6-K Pharvaris N.V. For: Jun 26 | SEC filing · Form 6-K | SEC EDGAR | -0.37% | +0.91% | |
| Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026 | Press release | GlobeNewswire | -1.25% | +0.80% | |
| Form 6-K Pharvaris N.V. For: Jun 11 | SEC filing · Form 6-K | SEC EDGAR | -0.86% | +2.19% | |
| Pharvaris Announces Annual General Meeting of Shareholders | Press release | GlobeNewswire | -0.86% | +2.19% | |
| Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 | Press release | GlobeNewswire | +0.38% | +0.70% | |
| Form 6-K Pharvaris N.V. For: May 12 | SEC filing · Form 6-K | SEC EDGAR | -0.97% | +2.81% | |
| Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.97% | +2.81% | |
| Form 6-K Pharvaris N.V. For: May 11 | SEC filing · Form 6-K | SEC EDGAR | -1.58% | +4.17% | |
| Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | -1.58% | +4.17% | |
| Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares | Press release | GlobeNewswire | -0.35% | -3.77% | |
| Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference | Press release | GlobeNewswire | -2.17% | +1.36% | |
| Form 20-F Pharvaris N.V. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -1.21% | +1.56% | |
| Form 6-K Pharvaris N.V. For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -1.21% | +1.56% | |
| Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.21% | +1.56% | |
| Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology | Press release | GlobeNewswire | -0.31% | +5.91% | |
| Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 | Press release | GlobeNewswire | -1.28% | -0.36% | |
| Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting | Press release | GlobeNewswire | -0.60% | +2.69% | |
| Form 6-K Pharvaris N.V. For: Jan 12 | SEC filing · Form 6-K | SEC EDGAR | -0.71% | +0.04% | |
| Pharvaris Outlines 2026 Strategic Priorities | Press release | GlobeNewswire | -0.71% | +0.04% | |
| Form 6-K Pharvaris N.V. For: Dec 03 | SEC filing · Form 6-K | SEC EDGAR | +1.28% | +21.75% | |
| Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks | Press release | GlobeNewswire | +1.28% | +21.75% | |
| Form 6-K Pharvaris N.V. For: Nov 12 | SEC filing · Form 6-K | SEC EDGAR | -0.04% | +7.50% | |
| Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.04% | +7.50% | |
| Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting | Press release | GlobeNewswire | +1.44% | +5.26% | |
| Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting | Press release | GlobeNewswire | +0.00% | -2.63% | |
| Form POSASR Pharvaris N.V. | SEC filing · Form POSASR | SEC EDGAR | +0.00% | -2.94% | |
| Form 6-K Pharvaris N.V. For: Sep 08 | SEC filing · Form 6-K | SEC EDGAR | +0.41% | +9.27% | |
| Form 6-K Pharvaris N.V. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -2.64% | -0.69% | |
| Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -2.64% | -0.69% | |
| Form 6-K Pharvaris N.V. For: Jul 24 | SEC filing · Form 6-K | SEC EDGAR | +1.68% | +1.58% | |
| Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | +1.68% | +1.58% | |
| Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants | Press release | GlobeNewswire | +1.05% | +4.15% | |
| Pharvaris Announces Proposed Public Offering of Ordinary Shares | Press release | GlobeNewswire | +1.05% | +4.15% | |
| Form 6-K Pharvaris N.V. For: Jul 10 | SEC filing · Form 6-K | SEC EDGAR | — | +7.66% | |
| Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 | Press release | GlobeNewswire | — | +7.66% | |
| Form 6-K Pharvaris N.V. For: Jun 27 | SEC filing · Form 6-K | SEC EDGAR | — | +4.70% | |
| Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit | Press release | GlobeNewswire | -0.06% | -5.50% | |
| Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress | Press release | GlobeNewswire | +0.00% | +0.71% | |
| Form 6-K Pharvaris N.V. For: Jun 10 | SEC filing · Form 6-K | SEC EDGAR | -0.69% | +0.67% | |
| Pharvaris Announces Annual Meeting of Shareholders | Press release | GlobeNewswire | -0.69% | +0.67% | |
| Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema | Press release | GlobeNewswire | — | -1.14% | |
| Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses | Press release | GlobeNewswire | — | +1.21% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PHVS section they belong to.
Where else PHVS is measured.
PHVS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Pharvaris N.V. - Ordinary Shares's median reaction calculated?
Every labeled PHVS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 286 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of PHVS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PHVS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.